Device Trial Radar · NCT06950021
Safety & Performance of CANOpus PINtuition Surgical Marker Navigation
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Nov 1, 2025
Study completion Feb 1, 2026
Sponsor
- Lead sponsor
- Sirius Medical Systems B.V.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Avania
- First posted
- Apr 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and performance of the Canopus Marker in adult breast cancer patients who are scheduled for breast-conserving surgery. The main questions it aims to answer are: 1. Can the Canopus Marker be safely and effectively used to mark tissue for surgical removal? 2. What is the satisfaction level of radiologists, surgeons, and patients with the use of the Canopus Marker? Participants will: * Have the Canopus Marker implanted into the tumor or nearby tissue using ultrasound guidance. * Undergo surgery where the Canopus Marker will help guide the surgeon to the tumor, and the marker will be removed along with the tumor. This surgery is performed using an FDA cleared and CE-marked detection device (Sirius Pintuition Detector). * Attend a follow-up visit two weeks after surgery to assess any adverse events and overall satisfaction.
Conditions
- Breast Surgery
- Lymph Node Excision
Interventions
Magnetic seedDevice
All patients enrolled will receive a single Sirius Canopus Marker with two anchors added to it for improved tissue fixation. Implantation will be done by a radiologist before breast conserving surgery, usually scheduled within a few days after Canopus Marker implantation. The Canopus Marker is removed with the specimen during the surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Performance: Retrieval RateTime frame: From enrolment to the follow-up visit at 2 weeks after surgery (estimated 3-5 weeks)
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rode Kruis Ziekenhuis
Beverwijk, North Holland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.